Ertapenem vs Gentamicin for UTI-ESBL in Patients with Impaired Renal Function

Introduction to Renal Impairment Considerations

The patient has impaired renal function, indicating moderate renal impairment, with elevated blood urea nitrogen (BUN) and creatinine levels 1, 2
Aminoglycosides like gentamicin are primarily excreted by the renal route and can accumulate in patients with impaired renal function, increasing toxicity risk 2, 3

Aminoglycosides are excreted in active form primarily by the renal route and can reach concentrations 25-100 fold higher than plasma levels in the urine 1, 4
Risk for nephrotoxicity increases significantly after 7 days of aminoglycoside therapy, but can occur earlier in patients with pre-existing renal impairment 5
Gentamicin use in patients with impaired renal function carries substantial risk, despite its excellent activity against many uropathogens including ESBL-producing organisms 1, 4

Ertapenem is a Group 1 carbapenem with excellent activity against ESBL-producing organisms 6, 7
Carbapenems are considered agents of choice for infections caused by ESBL-producing Enterobacteriaceae 7

Gentamicin has known nephrotoxicity and ototoxicity risks, which are amplified in patients with pre-existing renal impairment 1, 3
The risk-benefit ratio strongly favors ertapenem over gentamicin in a patient with already compromised renal function 2

Failing to recognize the increased risk of aminoglycoside nephrotoxicity in patients with pre-existing renal impairment 1, 3
Underestimating the cumulative nephrotoxicity risk when using gentamicin in a patient already experiencing renal dysfunction 3